Sunovion har också Latuda
Läkemedelsföretaget Sunovion skall starta FAS II studier med antipsykotikat SEP-363856 mot schizofreni och psykoser vid Parkinsons sjukdom.
Det nya antipsykotikat verkar ej genom blockering av dopmin-2-receptorer utan effekten är okänd.
Man tror att den kan stimulera 5-HT1A and TAAR1 receptorer samt att den också kan ha effekt mot negativa symptom.
Läs mer hos Businesswire.
"If these results are confirmed, this will be big, big news,” says Jeffrey Lieberman, a psychiatrist at Columbia University.
https://www.sciencemag.org/news/2020/04/experimental-schizophrenia-drug-could-reduce-long-neglected-symptoms
https://www.healio.com/psychiatry/schizophrenia/news/online/%7B9f8fa3dd-7071-4c9c-9037-aed8c5f992d9%7D/novel-psychotropic-agent-improves-symptoms-in-schizophrenia
After four weeks, patients taking SEP-363856 showed statistically significant and clinically meaningful improvement in the Positive and Negative Syndrome Scale (PANSS) total score (primary outcome) compared with placebo (-17.2 vs. -9.7; P=0.001, effect size = 0.45).
Safety and tolerability of SEP-363856 were generally similar to placebo
https://www.psychcongress.com/news/new-psychotropic-drug-schizophrenia-promising-early-testing
The placebo-controlled study met its primary endpoint, enrolling 245 hospitalized patients with acute worsening of schizophrenia and demonstrating improvements in a total syndrome scale over four weeks of daily treatment. Improvements were also seen in the overall severity of illness and psychopathology subscales.
https://www.fiercebiotech.com/biotech/sunovion-psychogenics-non-dopamine-schizophrenia-drug-meets-phase-2-endpoint